NRC NRC HEALTH

CIK 0000070487 41 ready 8-Ks latest April 28, 2026, 7:59 PM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline

Ready 8-Ks 41

Latest filing June 29, 2026, 1:04 PM ET

Top materiality 0.80

Event mix earnings ×20 · leadership ×9 · other_material ×6

Sentiment 11 pos · 6 neg · 24 neu

Latest earnings reported 2026-Q1

Executive change recent →

Recent 8-K filings for NRC

Highest-materiality recent filing

NRC Q4 2023 EPS $0.36; CFO Karas to retire March 31, dividend $0.12

February 13, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 5.02 item 9.01 ◈ executive_change ×2

Q4 2023 diluted EPS $0.36 vs $0.27; prior year included $0.10 Canadian exit charge.
Revenue flat at $38M as new core sales offset non-core revenue declines.

Read filing →

April 28, 2026, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01 ◈ Earnings Releases

NRC Health Q1 revenue up 4% to $34.8M; TRCV record $152.1M (+13% YoY)

GAAP net income $3.2M ($0.14 diluted EPS); adjusted net income $4.6M ($0.21 adjusted diluted EPS).
April 28, 2026, 7:59 PM ET other material materiality 0.75 neutral item 5.02

NRC Health amends exec stock awards, eliminates repurchase right; expects $9.4M Q2 expense

Committee amended grants to CEO Trent Green (500k shares), COO Helen Hrdy (100k), and Chief Corp Dev Officer Andrew Monich (100k) to eliminate repurchase right.
March 5, 2026, 6:59 PM ET other material materiality 0.60 positive item 7.01 item 9.01

NRC Health TRCV reaches all-time high of $152M, up 13% YoY

TRCV surpassed $152 million as of March 4, 2026, a new all-time high for NRC Health.
October 27, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02 item 9.01

NRC Health Q3 2025: TRCV up 8% to $141.7M; Adj EBITDA +11% YoY to $10.9M

Revenue $34.6M (+2% QoQ); GAAP net income $4.1M (12% of revenue); Adj net income $5.0M (14% of revenue).
August 28, 2025, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 item 9.01

NRC Health names Shane Harrison CFO effective Sept 25, 2025

Shane Harrison appointed Executive VP and CFO, succeeding Michael D. Hays as principal financial officer.
April 28, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 7.01 item 9.01

National Research Corporation Reports Q1 2025 Results and Announces Share Repurchase Program

Total recurring value contract value increased sequentially for second consecutive quarter.
March 4, 2025, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 9.01 ◈ executive_change ×3

NRC appoints Trent Green as CEO effective June 1, 2025; Hays becomes Chairman

Trent Green named CEO effective June 1, 2025; current CEO Mike Hays transitions to Chairman.
January 27, 2025, 6:59 PM ET earnings materiality 0.65 negative item 2.02 item 7.01 item 9.01

NRC Q4 revenue $36.9M, EPS $0.28; CTO Louvion resigns

Q4 revenue $36.9M vs $38.0M YoY; diluted EPS $0.28 vs $0.36.
November 14, 2024, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 ◈ executive_change

National Research CFO/PAO Linda Stacy to retire effective Dec 31, 2024

Linda Stacy notified company of retirement as Secretary, Principal Financial Officer, and Principal Accounting Officer.
October 25, 2024, 7:59 PM ET earnings materiality 0.70 negative item 2.02 item 9.01

NRC Health Q3 revenue falls 5.5% to $35.8M; EPS drops to $0.24 from $0.32

Revenue $35.8M vs $37.9M a year ago; diluted EPS $0.24 vs $0.32.
August 6, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 1.01 item 2.02 item 9.01

NRC Health Q2 revenue $35M, EPS $0.26; amends credit; acquires NOBL Health

Q2 revenue ~$35M vs ~$36M YoY; diluted EPS $0.26 vs $0.29 YoY; TRCV $138M at June 30.
February 13, 2024, 6:59 PM ET earnings materiality 0.80 positive item 2.02 item 5.02 item 9.01 ◈ executive_change ×2

NRC Q4 2023 EPS $0.36; CFO Karas to retire March 31, dividend $0.12

Q4 2023 diluted EPS $0.36 vs $0.27; prior year included $0.10 Canadian exit charge.
January 17, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02 item 7.01 item 9.01 ◈ executive_change

NRC Health promotes Hrdy to Chief Customer Officer, adds three execs, ties compensation to $170M TRCV target

Helen Hrdy promoted to CCO; Jason Hahn (CRO), Christophe Louvion (CPTO), Andy Monnich (CCDO) appointed.
February 16, 2023, 6:59 PM ET earnings materiality 0.70 neutral item 2.02 item 9.01 ◈ Earnings Releases

NRC Health reports Q4 EPS $0.27, down from $0.38; FY revenue +7% but EPS $1.27 vs $1.46

Q4 diluted EPS $0.27 (vs $0.38 in Q4 2021); full-year 2022 diluted EPS $1.27 (vs $1.46).
November 3, 2022, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01 ◈ Earnings Releases

National Research Corp Q3 revenue flat at $37.7M; EPS down to $0.33 from $0.38

Revenue $37.7M vs $37.8M prior year; net income $8.3M vs $9.7M; diluted EPS $0.33 vs $0.38.
August 4, 2022, 7:59 PM ET earnings materiality 0.60 negative item 2.02 item 9.01

NRC Health Q2 revenue up 2% to $37.3M; diluted EPS falls to $0.33 from $0.35

Revenue $37.3M (+2% YoY); net income $8.3M vs $8.9M; diluted EPS $0.33 vs $0.35.
May 5, 2022, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

National Research Corp Q1 revenue up 8% to $38.4M, EPS down to $0.34

Revenue $38.4M (+8% YoY), net income $8.5M vs $9.2M, diluted EPS $0.34 vs $0.36.
February 10, 2022, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

National Research Q4 revenue +10% to $38.3M, EPS $0.38; FY revenue +11% to $148.0M

Q4 2021 revenue $38.3M (+10% YoY); operating income $12.9M (+26%); diluted EPS $0.38 vs $0.32.
November 4, 2021, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

National Research Q3 revenue up 13% to $37.8M; EPS $0.38 vs $0.37

Revenue $37.8M (+13% YoY); operating income $13.1M (+9%).
August 5, 2021, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01

National Research Q2 revenue up 17% to $36.4M; EPS rises to $0.35 from $0.30

Total Recurring Contract Value grew 5% YoY to $149.8M.

Executive changes

Appointed

Jordan N. Freeman

Chief Accounting Officer

NRC · NRC HEALTH

Effective: 2025-04-18
Filed: April 22, 2025, 7:59 PM ET

appointed Jordan N. Freeman as the Company’s Chief Accounting Officer.

Role change (interim)

Michael D. Hays

principal financial officer

NRC · NRC HEALTH

Effective: 2025-04-18
Filed: April 22, 2025, 7:59 PM ET

designated Michael D. Hays, the Company’s Chief Executive Officer, to serve as the Company’s principal financial officer.

Appointed

Trent Green

Chief Executive Officer

NRC · NRC HEALTH

Effective: 2025-06-01
Filed: April 9, 2025, 7:59 PM ET

the board of directors of National Research Corporation, a Delaware corporation (the “Company”) appointed Trent Green as our Chief Executive Officer and to serve as a director, both effective June 1, 2025.

Appointed (interim)

Linda Stacy

Interim Principal Financial Officer

NRC · NRC HEALTH

Effective: 2025-02-26
Filed: March 4, 2025, 6:59 PM ET

the Board appointed Linda Stacy to serve as Interim Principal Financial Officer until March 31, 2025

Role change

Micheal D. Hays

Chairman

NRC · NRC HEALTH

Effective: 2025-06-01
Successor: Trent Green
Filed: March 4, 2025, 6:59 PM ET

Micheal D. Hays, the Company’s current Chief Executive Officer, will transition to the role of Chairman

Appointed

Trent Green

Chief Executive Officer

NRC · NRC HEALTH

Effective: 2025-06-01
Filed: March 4, 2025, 6:59 PM ET

the Board appointed Trent Green as the Company’s Chief Executive Officer and to serve as a director, both effective June 1, 2025

Departed

Linda Stacy

Secretary, Principal Financial Officer, and Principal Accounting Officer

NRC · NRC HEALTH

Effective: 2024-12-31
Filed: November 14, 2024, 6:59 PM ET

On November 8, 2024, Linda Stacy, Secretary, Principal Financial Officer, and Principal Accounting Officer of National Research Corporation (the “Company”), notified the Company of her decision to retire effective December 31, 2024.

Appointed

Helen L. Hrdy

Chief Operating Officer

NRC · NRC HEALTH

Effective: 2024-10-14
Filed: October 15, 2024, 7:59 PM ET

On October 14, 2024, the Board of Directors of National Research Corporation, a Delaware corporation (the "Company"), appointed Helen L. Hrdy as the Company’s Chief Operating Officer.

Role change

Linda Stacy

Principal Financial Officer

NRC · NRC HEALTH

Effective: 2024-05-07
Filed: May 7, 2024, 7:59 PM ET

On May 7, 2024, the Company’s Board of Directors appointed Linda Stacy as the Company’s Principal Financial Officer.

Appointed

Linda Stacy

Principal Accounting Officer

NRC · NRC HEALTH

Effective: 2024-03-31
Filed: February 13, 2024, 6:59 PM ET

Also, on February 8, 2024, the Company’s Board of Directors approved the promotion of Linda Stacy, Vice President of Finance, to the position of Principal Accounting Officer, effective on March 31, 2024.

Departed

Kevin R. Karas

Chief Financial Officer

NRC · NRC HEALTH

Effective: 2024-03-31
Filed: February 13, 2024, 6:59 PM ET

On February 8, 2024, Kevin R. Karas, Senior Vice President, Chief Financial Officer, Treasurer and Secretary of the Company notified the Company of his decision to retire effective March 31, 2024.

Role change

Helen L. Hrdy

Chief Customer Officer

NRC · NRC HEALTH

Effective: 2024-01-16
Filed: January 17, 2024, 6:59 PM ET

On January 16, 2024, Helen L. Hrdy was promoted to the position of Chief Customer Officer of National Research Corporation, a Delaware corporation (the “Company”).

Earnings & guidance

2026-Q1 EPS reported $0.14 filing →

Materiality & sentiment trend

Max materiality 0.80 · Median 0.55 · Most common event earnings

11 positive 6 negative 24 neutral

source · NRC on sec.gov